Favorable tolerability was shown with no increase in skin reactions after 2 weeks2
The safety and efficacy of once-daily ARAZLO Lotion were assessed in 2 multicenter, randomized, double-blind Phase 3 clinical trials of 1,614 subjects 9 years of age and older with facial acne vulgaris. Enrolled subjects had a score of moderate (3) or severe (4) on the Evaluator’s Global Severity Score (EGSS), 20 to 50 inflammatory lesions (papules, pustules, and nodules), 25 to 100 noninflammatory lesions (open and closed comedones), and 2 or fewer facial nodules. The coprimary efficacy endpoints of success on the EGSS, absolute change in noninflammatory lesion count, and absolute change in inflammatory lesion count were assessed at Week 12.3
The safety and efficacy of ARAZLO Lotion were assessed in a multicenter, randomized, double-blind, vehicle-controlled Phase 2 clinical trial of 210 subjects aged 12 years and older with acne vulgaris. Subjects had a score of moderate (3) or severe (4) on the Evaluator’s Global Severity Score (EGSS), 20 to 40 inflammatory lesions, 20 to 100 noninflammatory lesions, and 2 nodules or less. Subjects were randomized to receive ARAZLO Lotion 0.045%, tazarotene cream 0.1%, or respective vehicle. The Week 12 coprimary endpoints included: mean absolute change in inflammatory and noninflammatory lesion counts; and percentage of subjects with at least a 2-grade reduction in EGSS and scores of clear (0) or almost clear (1).1
If you are a US healthcare professional and want clinical information on ARAZLO Lotion, please click Continue.